These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 37178240)

  • 1. Occurrence of fever in cell-free and concentrated ascites reinfusion therapy is not related to the primary disease or nature of ascites.
    Fukunaga S; Egawa M; Ito T; Tanabe K
    J Artif Organs; 2024 Jun; 27(2):138-145. PubMed ID: 37178240
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characteristics of Patients and Their Ascites Who Underwent Repeated Cell-Free and Concentrated Ascites Reinfusion Therapy.
    Maeda S; Yabuuchi J; Nobuta H; Makiishi T; Hirose K
    Ther Apher Dial; 2015 Aug; 19(4):342-8. PubMed ID: 26386222
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adverse effects of cell-free and concentrated ascites reinfusion therapy for malignant ascites: a single-institute experience.
    Tsubokura M; Adegawa Y; Kojima M; Tanosaki R; Ohtake R; Kase Y; Iwashita N; Kasane M; Nakabayashi S; Takeuchi S; Kato K; Boku N; Kanemitsu Y; Okusaka T; Fujimoto H; Yonemori K; Ishiki H; Kawamura K; Satomi E; Matsushita H
    BMC Cancer; 2022 Mar; 22(1):268. PubMed ID: 35287609
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and efficacy of cell-free and concentrated ascites reinfusion therapy (CART) in refractory ascites: Post-marketing surveillance results.
    Hanafusa N; Isoai A; Ishihara T; Inoue T; Ishitani K; Utsugisawa T; Yamaka T; Ito T; Sugiyama H; Arakawa A; Yamada Y; Itano Y; Onodera H; Kobayashi R; Torii N; Numata T; Kashiwabara T; Matsuno Y; Kato M
    PLoS One; 2017; 12(5):e0177303. PubMed ID: 28510606
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Changes in Coagulation and Fibrinolytic Factors in Patients With Cirrhotic Refractory Ascites Undergoing Cell-free and Concentrated Ascites Reinfusion Therapy: A Retrospective Observational Study in Japan.
    Yorioka N; Namisaki T; Shibamoto A; Suzuki J; Kubo T; Iwai S; Tomooka F; Tanaka M; Takeda S; Fujimoto Y; Enomoto M; Muarata K; Inoue T; Tsuji Y; Fujinaga Y; Nishimura N; Kitagawa K; Takaya H; Kaji K; Kawaratani H; Akahane T; Mitoro A; Yamazaki M; Yoshiji H
    In Vivo; 2023; 37(3):1226-1235. PubMed ID: 37103093
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cell-free and concentrated ascites reinfusion therapy (CART) for management of massive malignant ascites in gastric cancer patients with peritoneal metastasis treated with intravenous and intraperitoneal paclitaxel with oral S-1.
    Yamaguchi H; Kitayama J; Emoto S; Ishigami H; Ito T; Hanafusa N; Watanabe T
    Eur J Surg Oncol; 2015 Jul; 41(7):875-80. PubMed ID: 25986856
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Single center experience of cell-free and concentrated ascites reinfusion therapy in malignancy related ascites.
    Ito T; Hanafusa N; Fukui M; Yamamoto H; Watanabe Y; Noiri E; Iwase S; Miyagawa K; Fujita T; Nangaku M
    Ther Apher Dial; 2014 Feb; 18(1):87-92. PubMed ID: 24499089
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Cell-Free Ascites Reinfusion Therapy(CART)Modified by Keisuke Matsusaki(KM-CART)at Our Hospital].
    Iwaki R; Shindo K; Kawahara H; Nanba N; Kuramoto Y; Beppu T; Uesugi T; Tanaka Y; Uesugi Y
    Gan To Kagaku Ryoho; 2018 Dec; 45(13):2165-2167. PubMed ID: 30692319
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ascitic IL-10 Concentration Predicts Prognosis of Patients Undergoing Cell-Free and Concentrated Ascites Reinfusion Therapy.
    Ito T; Hanafusa N; Iwase S; Noiri E; Nangaku M; Nakagawa K; Miyagawa K
    Ther Apher Dial; 2020 Feb; 24(1):90-95. PubMed ID: 31157953
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Usefulness of cell-free and concentrated ascites reinfusion therapy in the therapeutic management of advanced ovarian cancer patients with massive ascites.
    Kawata Y; Nagasaka K; Matsumoto Y; Oda K; Tanikawa M; Sone K; Mori-Uchino M; Tsuruga T; Arimoto T; Osuga Y; Fujii T
    Int J Clin Oncol; 2019 Apr; 24(4):420-427. PubMed ID: 30474762
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel cell-free and concentrated ascites reinfusion therapy (KM-CART) for refractory ascites associated with cancerous peritonitis: its effect and future perspectives.
    ; Matsusaki K; Ohta K; Yoshizawa A; Gyoda Y
    Int J Clin Oncol; 2011 Aug; 16(4):395-400. PubMed ID: 21347629
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of reinfusion of concentrated ascitic fluid for malignant ascites: a concept-proof study.
    Hanada R; Yokomichi N; Kato C; Miki K; Oyama S; Morita T; Kawahara R
    Support Care Cancer; 2018 May; 26(5):1489-1497. PubMed ID: 29168037
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improvement of Major Problems in the Cell-Free and Concentrated Ascites Reinfusion Therapy System─Constructing of Cell-Free and Concentrated Ascites Reinfusion Therapy System Using External Pressure for Filtration.
    Yoshizawa M; Nakatsuji Y
    Ther Apher Dial; 2019 Jun; 23(3):233-236. PubMed ID: 31033153
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cell-free and Concentrated Ascites Reinfusion Therapy for Refractory Ascites in Cirrhosis in Post-marketing Surveillance and the Role of Tolvaptan.
    Iwasa M; Ishihara T; Kato M; Isoai A; Kobayashi R; Torii N; Soneda N; Takei Y
    Intern Med; 2019 Nov; 58(21):3069-3075. PubMed ID: 31292400
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Feasibility of a fast-track randomized controlled trial of cell-free and concentrated ascites reinfusion therapy for patients with refractory malignant ascites.
    Yokomichi N; Imai K; Sakamoto M; Horiki M; Yamauchi T; Miwa S; Inoue S; Uneno Y; Suzuki H; Wada T; Ichikawa Y; Morita T
    BMC Cancer; 2022 Feb; 22(1):218. PubMed ID: 35227250
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cell-Free and Concentrated Ascites Reinfusion Therapy for Decompensated Liver Cirrhosis.
    Kozaki K; IInuma M; Takagi T; Fukuda T; Sanpei T; Terunuma Y; Yatabe Y; Akano K
    Ther Apher Dial; 2016 Aug; 20(4):376-82. PubMed ID: 27523078
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and efficacy of cell-free and concentrated ascites reinfusion therapy against cirrhotic ascites in comparison with malignancy-related ascites.
    Ito T; Hanafusa N; Soneda N; Isoai A; Kobayashi R; Torii N; Kato M
    J Gastroenterol Hepatol; 2021 Nov; 36(11):3224-3232. PubMed ID: 34250635
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Endotoxin Activity Reflects an Increase in Body Temperature in Cirrhotic Patients With Ascites Undergoing Cell-free and Concentrated Ascites Reinfusion Therapy.
    Namisaki T; Tsuji Y; Kitade M; Yorioka N; Fujinaga Y; Sawada Y; Nishimura N; Kitagawa K; Inoue T; Takaya H; Kaji K; Kawaratani H; Moriya K; Akahane T; Mitoro A; Yoshiji H
    In Vivo; 2022; 36(3):1477-1484. PubMed ID: 35478114
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Verification of serum albumin elevating effect of cell-free and concentrated ascites reinfusion therapy for ascites patients: a retrospective controlled cohort study.
    Yamada Y; Inui K; Hara Y; Fuji K; Sonoda K; Hashimoto K; Kamijo Y
    Sci Rep; 2019 Jul; 9(1):10195. PubMed ID: 31308465
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Cell-free and concentrated ascites reinfusion therapy(CART)].
    Yoshizawa A; Gyouda Y; Ishiguro T; Matsuzaki K; Yoshizawa T
    Gan To Kagaku Ryoho; 2012 Dec; 39 Suppl 1():33-5. PubMed ID: 23268893
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.